Greenyn Biotechnology Co., Ltd.
TTPEX:684657.90
TWD
-0.40
(-0.69%)
ISIN
TW0006846009
Return %
Stock
S&P 500
1Y
-21.54
14.20
3Y
-23.82
81.12
5Y
- -
68.34
Capital Structure
TWD
•
in mil. unless spec.Working Capital
TWD
•
in mil. unless spec.Growth Rates
TWD
•
in mil. unless spec.Quarterly Revenue
TWD
•
in mil. unless spec.Quarterly Earnings Per Share
TWD
•
in mil. unless spec.Quarterly Dividends Per Share
TWD
•
in mil. unless spec.Company Description
- CEO
- Pang Kuei Hsu
- Full Time Employees
- 143
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- No. 43, Keya Road Taichung TX Taiwan 428
- IPO Date
- May 15, 2023
- Website
- greenynbio.com
- Similar Companies
- Business
- Greenyn Biotechnology Co., Ltd (6846.TWO) develops and manufactures botanical extraction equipment and related solutions for the biotechnology and natural product industries. The company offers core products including supercritical CO2 extraction systems, ultrasonic extraction equipment, spray drying machines, and distillation units; services encompass customized system design, installation, maintenance, and technical consulting for herbal extraction processes. Headquartered in Taoyuan, Taiwan, Greenyn was founded in 2012 and primarily serves customers in the nutraceutical, cosmetics, food and beverage, and pharmaceutical sectors across Asia, with expanding operations in Europe and North America. Greenyn Biotechnology operates within the industrial machinery segment focused on green extraction technologies, targeting manufacturers seeking sustainable alternatives to chemical solvents for plant-based compounds. Its equipment supports production of high-purity extracts such as essential oils, cannabinoids, and polyphenols, emphasizing energy efficiency and compliance with international standards like GMP and FDA guidelines. The company maintains a network of subsidiaries and partnerships in key markets to facilitate global distribution and after-sales support. In recent developments, Greenyn Biotechnology announced a strategic partnership with a leading European nutraceutical firm in early 2025 to co-develop next-generation CO2 extraction systems optimized for hemp and medicinal plant processing, enhancing its presence in the burgeoning cannabis-derived product market. The company secured a NT$500 million funding round in late 2024 led by domestic venture capital, earmarked for R&D expansion and capacity upgrades at its Taoyuan facility. Additionally, Greenyn launched its GYN-SuperCritic 500L series in mid-2025, featuring AI-integrated controls for 20% higher yield efficiency, marking a shift toward smart manufacturing solutions.